Study details
Enrolling now
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Danielle Wallace
NCT IDNCT06828991ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 4.7 years
Ages
70+
Locations
1 site in NY
About this study
This trial is testing whether adding mosunetuzumab to treatment can help older patients with DLBCL who have detectable ctDNA in their blood. The goal is to see if this approach leads to better disease control and outcomes for these patients, as well as assess the safety of this regimen.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Mosunetuzumab
- 2.Use ClonoSEQ
PhasePhase 2
DrugMosunetuzumab
Primary goalctDNA clearance rate after mosunetuzumab treatment
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
mosunetuzumab
Endpoints
Primary: ctDNA clearance rate after mosunetuzumab treatment
Secondary: Objective response rate and complete response rate of pola-R-mini-CHP